Accelerate to discover

Back to filter

Related topics

Elevated NSD3 histone methylation activity drives squamous cell lung cancer

Spectral Instruments Imaging

Jun 8, 2021

This work identifies NSD3 as a principal 8p11-12 amplicon-associated oncogenic driver in LUSC, and suggests that...

Jun 20, 2021

IncuCyte webinar recording: How to measure Immune Cell Killing of Tumor Cells effectively

Sartorius

Jun 4, 2021

Immuno-oncology (IO) has transformed cancer treatment. The number of treatments in the IO pipeline continues to...

White Paper: Immunophenotyping Rare Immune Cells with Laminar Wash AUTO System

Curiox

Jun 3, 2021

The Laminar Wash (LW) AUTO system consists of a wall-less plate and a laminar flow cell washer that enable automated...

A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic

Tonbo Biosciences

Jun 3, 2021

Tonbo Biosciences flow cytometry reagents & antibodies are manufactured with the highest quality and precision and...

Jun 20, 2021

Cytek webinar : Evaluating Spectral Cytometry for Immune Profiling in Viral Disease

Cytek Biosciences

May 13, 2021

In conventional fluorescence cytometry, each fluorophore in a panel is measured in a target detector, through the use...

Show all topics (10)

Mutual destruction of deep Lung tumor tissues by nanodrug‐conjugated and CQ1 imaging cytometer

Jun 1, 2018

The 10‐year survival rate of cancer patients has greatly increased over the last 20 years. However, the survival rate of patients with major malignant tumors, such as lung and pancreatic cancers, still shows negligible improvement.The conventional chemotherapeutic strategy for treating lung cancer remains unsatisfactory in this respect. Specifically, the 5‐year survival rates of both non‐small‐cell lung cancer (NSCLC) and small cell lung cancer (SCLC) patients exhibited merely 4–5% improvements in the past decade for cancer in stages I–III.2 The main difficulty in treating lung cancer is the lack of targeted chemotherapeutic agents specific to the lung tumor tissues and, thus, non‐specific targeting generally leads to unwanted side effects induced by excessive doses of chemotherapeutic agents.

Several strategies have been introduced to resolve the aforementioned issues, such as cancer antigen‐targeted monoclonal antibody (mAb) therapy,4 nanodrug delivery,5 and cell‐mediated therapy (i.e., T‐cell‐based therapy for NSCLC6). However, many clinical trials have shown that intravenously administered mAb, particularly epidermal growth factor receptor‐targeting mAbs, induced dermatological toxicities (e.g., acneiform eruption, xerosis, telangiectasia, hyperpigmentation, fissures, and hair/nail changes) in over 50% of patients after treatment.

Read more!

Scientific paper
Application

Get more info

Riccardo Pasculli

Head of application support

Riccardo

Pasculli

+420 731 127 717

Send Message

Brand profile

Yokogawa

Yokogawa is a leading provider of confocal quantitative live cell imaging platforms. Combining superior technology with engineering services, project management, and maintenance, Yokogawa delivers field proven operational efficiency, safety, quality, and reliability. 

Related products

Confocal quantitative image cytometer CQ1 offers a new approach to image quantification

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey